| 2025-12-03 |
详情>>
内部人交易：
Hefti Brenda股份增加30170.00股
|
| 2025-11-04 |
详情>>
股本变动：
变动后总股本26811.22万股
|
| 2025-11-04 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.97美元,归母净利润5.38亿美元,同比去年增长41.07%
|
| 2025-11-04 |
财报披露：
美东时间 2025-11-04 盘后发布财报
|
| 2025-07-28 |
详情>>
业绩披露：
2025年中报每股收益1.25美元,归母净利润3.44亿美元,同比去年增长30.76%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益0.57美元,归母净利润1.60亿美元,同比去年增长327.73%
|
| 2025-04-16 |
股东大会：
将于2025-05-28召开股东大会
会议内容 ▼▲
- 1.To elect the eleven nominees for director to hold office until the next annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 2, 2026 .
3.To approve, on an advisory basis, the compensation of Exelixis’ Named Executive Officers, as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting (Say on Pay).
4.To conduct any other business properly brought before the meeting.
|
| 2025-02-11 |
详情>>
业绩披露：
2022年年报每股收益0.57美元,归母净利润1.82亿美元,同比去年增长-21.11%
|
| 2025-02-11 |
详情>>
业绩披露：
2024年年报每股收益1.80美元,归母净利润5.21亿美元,同比去年增长150.89%
|
| 2024-10-29 |
详情>>
业绩披露：
2024年三季报(累计)每股收益1.31美元,归母净利润3.81亿美元,同比去年增长212.00%
|
| 2024-10-15 |
复牌提示：
2024-10-15 11:00:43 停牌，复牌日期 2024-10-15 11:05:43
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益0.37美元,归母净利润1.21亿美元,同比去年增长-12.95%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益0.89美元,归母净利润2.63亿美元,同比去年增长117.34%
|
| 2024-04-30 |
详情>>
业绩披露：
2024年一季报每股收益0.12美元,归母净利润3731.70万美元,同比去年增长-6.77%
|
| 2024-04-18 |
股东大会：
将于2024-05-30召开股东大会
会议内容 ▼▲
- 1.To elect the eleven nominees for director to hold office until the next annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 3, 2025.
3.To approve an amendment and restatement of the Exelixis, Inc. 2000 Employee Stock Purchase Plan to, among other things, increase the number of shares authorized for issuance by 6,000,000 shares.
4.To approve, on an advisory basis, the compensation of Exelixis’ Named Executive Officers, as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting (Say on Pay).
5.To conduct any other business properly brought before the meeting.
|
| 2024-02-06 |
详情>>
业绩披露：
2023年年报每股收益0.65美元,归母净利润2.08亿美元,同比去年增长13.98%
|
| 2023-11-01 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.38美元,归母净利润1.22亿美元,同比去年增长-42.46%
|
| 2023-05-03 |
股东大会：
将于2023-05-31召开股东大会
会议内容 ▼▲
- 1.To elect Farallon’s slate of three nominees — Tomas J. Heyman, David E. Johnson and Robert “Bob” Oliver, Jr. (each, a “Farallon Nominee” and collectively, the “Farallon Nominees” and together with Farallon and Caligan, the “Participants”) — to serve as directors of the Company and hold office until the Company’s 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified.
2.To ratify the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 29, 2023.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers.
4.To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company’s named executive officers.
5.To conduct any other business properly brought before the Annual Meeting.
|
| 2022-04-14 |
股东大会：
将于2022-05-25召开股东大会
会议内容 ▼▲
- 1.To elect the eleven nominees for director named in the Proxy Statement accompanying this Notice of Annual Meeting to hold office until the next annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 30, 2022.
3.To amend and restate the Exelixis, Inc. 2017 Equity Incentive Plan to, among other things, increase the number of shares authorized for issuance by 28,500,000 shares.
4.To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting.
5.To conduct any other business properly brought before the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-15 |
股东大会：
将于2021-05-26召开股东大会
会议内容 ▼▲
- 1.To elect the eleven nominees for director named in the Proxy Statement accompanying this Notice of Annual Meeting to hold office until the next annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her death, resignation or removal.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting.
4.To conduct any other business properly brought before the meeting.
|
| 2020-04-09 |
股东大会：
将于2020-05-20召开股东大会
会议内容 ▼▲
- 1.To elect the eleven nominees for director named in the Proxy Statement accompanying this Notice of Annual Meeting to hold office until the next annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her death, resignation or removal.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 1, 2021.
3.To amend and restate the Exelixis 2017 Equity Incentive Plan (2017 Plan) to, among other things, increase the number of shares authorized for issuance by 21,000,000 shares.
4.To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting.
5.To conduct any other business properly brought before the meeting.
|
| 2019-04-11 |
股东大会：
将于2019-05-22召开股东大会
会议内容 ▼▲
- 1.To elect the five Class II nominees for director named in the Proxy Statement accompanying this Notice to hold office until the 2022 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 3, 2020.
3.To approve the proposal of Exelixis’ Board of Directors to amend Exelixis’ Amended and Restated Certificate of Incorporation to declassify the Board of Directors to provide for annual elections by the 2020 Annual Meeting of Stockholders.
4.To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
5.To conduct any other business properly brought before the meeting.
|
| 2018-04-12 |
股东大会：
将于2018-05-23召开股东大会
会议内容 ▼▲
- 1.To elect the three Class I nominees for director named in the Proxy Statement accompanying this Notice to hold office until the 2021 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 28, 2018.
3.To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
4.To conduct any other business properly brought before the meeting.
|
| 2017-04-13 |
股东大会：
将于2017-05-24召开股东大会
会议内容 ▼▲
- 1.To elect the four Class III nominees for director named in the Proxy Statement accompanying this Notice to hold office until the 2020 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 29, 2017.
3.To approve the Exelixis, Inc. 2017 Equity Incentive Plan (the “2017 Equity Plan”). A copy of the 2017 Equity Plan is attached to the Proxy Statement accompanying this Notice as Appendix A.
4.To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
5.To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of Exelixis’ named executive officers.
6.To conduct any other business properly brought before the meeting.
|
| 2016-04-13 |
股东大会：
将于2016-05-25召开股东大会
会议内容 ▼▲
- 1.To elect the three Class II nominees for director named in the Proxy Statement accompanying this Notice to hold office until the 2019 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 30, 2016.
3.To approve an amendment and restatement of the Exelixis, Inc. 2000 Employee Stock Purchase Plan (the “2000 Purchase Plan”) to increase the number of shares of common stock reserved for issuance under the 2000 Purchase Plan by 5,000,000 shares and make certain other changes as described in Proposal 3. A copy of the 2000 Purchase Plan, as amended, is attached to the Proxy Statement accompanying this Notice as Appendix A.
4.To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
5.To conduct any other business properly brought before the meeting.
|